Mission & Vision
We’re advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Our CEO, Brent Vaughan speaks about the promise of neuromodulation to improve the lives of millions of Alzheimer’s patients.
Our Novel Platform
Introducing our novel platform for neurodegenerative disease
Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease.
Our Pipeline
Leveraging our platform across multiple neurodegenerative diseases.
Focus
CogTx-001
Alzheimer’s Disease
CogTx-002
Mild Cognitive Impairment
CogTx-003
Parkinson's Disease
CogTx-004
TBI-related Dementia
CogTx-005
Ischemic Stroke
CogTx-006
Multiple Sclerosis
Discovery
Preclinical
Early Clinical
Pivotal Clinical
In market
Latest News & Updates
Stay up to date
Mar 14, 2022
Ushering in a New Class of Disease-Modifying DTx
Mar 11, 2022
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
Mar 7, 2022
Fierce Medtech's 2021 Fierce 15
Jan 27, 2022
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
Careers
Join our growing team
Clinical Affairs
Clinical Trial Manager
Remote
Design
Industrial Designer
Cambridge, MA
Engineering
Signal Processing Scientist/Engineer
Cambridge, MA